The nitroxides pirolin and pirolid protect the plasma membranes of rat cardiomyocytes against damage induced by anthracyclines.
This study was performed to evaluate the protective effects of pyrroline and pyrrolidine nitroxides Pirolin, PL, and Pirolid, PD, on the plasma membranes of rat cardiomyocytes treated in vitro with anthracycline drugs aclarubicin (ACL) and doxorubicin (DOX). The influence of two concentrations of drugs (10 and 20 microM) and nitroxides (0.1 and 1 mM) as well as their combinations (a drug and a nitroxide) on membrane fluidity was investigated. The plasma membranes of cardiomyocytes were labelled with a hydrophobic fluorescence probe 12-AS and membrane fluidity was estimated on the basis of the fluorescence anisotropy of the probe. We found that aclarubicin and doxorubicin induced a significant dose-dependent decrease in membrane fluidity, whereas the nitroxides (PL and PD) caused its increase. Preincubation of cardiomyocytes with Pirolin entirely protected plasma membranes of these cells against damage caused by DOX. In the same conditions no protective effect of Pirolid was observed. What is more, Pirolid in combination with DOX caused fluidisation of the plasma membranes of cardiomyocytes. Both nitroxides at low concentration (0.1 mM) protected plasma membranes against rigidification induced by aclarubicin, while high concentration (1 mM) was ineffective and caused fluidisation of the plasma membranes of cardiomyocytes.
Koceva-Chyła
Aneta
A
Department of Thermobiology, University of Łódź, Poland.
Sokal
Adam
A
Kania
Katarzyna
K
Gwoździński
Krzysztof
K
Jóźwiak
Zofia
Z
D015250:Aclarubicin / Q000037:antagonists & inhibitors / Q000633:toxicity; D000818:Animals; D018943:Anthracyclines / Q000037:antagonists & inhibitors / Q000633:toxicity*; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors / Q000633:toxicity; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D003497:Cyclic N-Oxides / Q000494:pharmacology*; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000633:toxicity; D005454:Fluorescence Polarization; D005456:Fluorescent Dyes; D066298:In Vitro Techniques; D008297:Male; D008560:Membrane Fluidity / Q000187:drug effects; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000378:metabolism; D009589:Nitrogen Oxides / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013229:Stearic Acids
C575622:3-carbamoyl-2,2,5,5-tetramethylpyrroline-1-oxyl; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D003497:Cyclic N-Oxides; D005456:Fluorescent Dyes; D009589:Nitrogen Oxides; D011758:Pyrroles; D011759:Pyrrolidines; D013229:Stearic Acids; C026653:12-(9-anthroyloxy)stearic acid; C013231:pyrroline; D015250:Aclarubicin; D004317:Doxorubicin; C032519:pyrrolidine